PEG-interferon α-2b plus ribavirin for treatment of patients with chronic hepatitis C who have previously failed to achieve a sustained virologic response following interferon α or interferon α-2b plus ribavirin therapy: Mark Sulkowski, Johns Hopkins Medical Institutions, Baltimore, MD; Kenneth D Rothstein, Albert Einstein Medical Ctr, Philadelphia, PA; Lawrence Stein, Florham Park, New Jersey, Florham Park, NJ; Eliot Godofsky, Bradenton, Florida, Bradenton, FL; David Shoultz, PPD Development and University of Washington, Seattle, WA; Russ Hudnall, Mary Huff, Hepatitis Resource Network, Tacoma, WA; Douglas Dieterich, New York University School of Medicine, New York, NY